Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 2c; Adjusts FY12 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Says Watch for Bottom in Endo Pharma (ENDP)
November 6, 2012 1:05 PM ESTJefferies maintained a Buy on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) but cut its price target of $36.00 (from $42.00) in the wake of the companys weak Q3 earnings report and lower guidance.
"Sentiment couldn't get much worse now, and [Monday's]... More
